Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients

NCT05141058 is registered in ClinicalTrials.gov with Children's National Research Institute as lead sponsor.

NCT NCT05141058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05141058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients
Lead sponsor
Children's National Research Institute
Phase
Phase 1
Overall status
Recruiting
Start date
October 19, 2021
Completion date
December 15, 2029
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2 infection